ACXP
NASDAQAcurx Pharmaceuticals Inc.
Price$1.62-0.01 (-0.61%)
01:30 PM04:30 PM
News · 26 weeks37-100%
2025-12-142026-06-07
Mix2890d
- SEC Filings12(43%)
- Insider8(29%)
- Other3(11%)
- Offering3(11%)
- Earnings2(7%)
Latest news
25 items- SECSEC Form 424B3 filed by Acurx Pharmaceuticals Inc.424B3 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
- SECSEC Form 424B3 filed by Acurx Pharmaceuticals Inc.424B3 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
- PRAcurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business UpdateSTATEN ISLAND, N.Y., May 12, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the first quarter ended March 31, 2026. Highlights of the first quarter ended March 31, 2026, or in some cases shortly thereafter, include:In February 2026, we announced that the USPTO granted a new patent for our DNA pol IIIC inhibitors covering composition of matter and method of use. This patent extends to December 2039, subject to extension under US patent rules. This adds to our extensi
- SECSEC Form EFFECT filed by Acurx Pharmaceuticals Inc.EFFECT - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
- SECSEC Form EFFECT filed by Acurx Pharmaceuticals Inc.EFFECT - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
- SECSEC Form 10-Q filed by Acurx Pharmaceuticals Inc.10-Q - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
- SECSEC Form S-1 filed by Acurx Pharmaceuticals Inc.S-1 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
- SECSEC Form S-1 filed by Acurx Pharmaceuticals Inc.S-1 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
- PRAcurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026DNA pol IIIC inhibitors demonstrate the unexpected benefit of gut microbiome preservation while demonstrating systemic antibacterial activityNeutropenic CD-1 mice were infected intramuscularly with methicillin-resistant Staphylococcus aureus (MRSA) and subsequently treated with one of three Acurx DNA pol IIIC inhibitors, linezolid, or placebo administered orallyAcurx compounds achieved potentially therapeutic plasma levels and reduced MRSA tissue burdenAcurx antibiotics maintained a substantially higher gut microbial diversity and a community structure similar to baseline and distinct from linezolidUnlike linezolid, ACX compounds maintain Bacteroidota-dominant community structure and prevent
- SECSEC Form D filed by Acurx Pharmaceuticals Inc.D - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
- PRAcurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company ShowcaseSTATEN ISLAND, N.Y., April 29, 2026 /PRNewswire/ -- Acurx Pharmaceuticals (NASDAQ:ACXP) (Acurx or the Company), a fully-integrated biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections announced today that David P. Luci, President & Chief Executive Officer, will participate virtually in a fireside chat at A.G.P.'s Healthcare Company Showcase on Wednesday, May 24, 2025. A replay of the presentation will be available under the News / Events tab of the Acurx website following the event at www.acurxpharma.com.About Acurx Pharmaceuticals, Inc.Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of s
- INSIDERSEC Form 4 filed by Sailer Carl4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
- INSIDERSEC Form 4 filed by Dean Jack H4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
- INSIDERSEC Form 4 filed by Donohue James J.4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
- INSIDERSEC Form 4 filed by Harrison Thomas L4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
- INSIDERSEC Form 4 filed by Scodari Joseph C4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
- INSIDERSEC Form 4 filed by Deluccia Robert J4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
- INSIDERSEC Form 4 filed by Luci David P4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
- INSIDERSEC Form 4 filed by Shawah Robert G.4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
- PRAcurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business UpdateSTATEN ISLAND, N.Y., April 20, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its first quarter 2026 financial results on Tuesday, May 12, 2026 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:Date: Tuesday, May 12, 2026Time: 8:00 a.m. ET Toll fr
- PRAcurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules$2.5 million upfront with up to an additional $4.6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrantsSTATEN ISLAND, N.Y., April 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced the closing of its previously announced registered direct offering of 825,085 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.03 per share (or pre-funded warrant in lieu thereof) priced at-the-market under Nasdaq rules. In addition, in a con
- SECAcurx Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
- SECSEC Form 424B5 filed by Acurx Pharmaceuticals Inc.424B5 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
- PRAcurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules$2.5 million upfront with up to an additional $4.6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrantsSTATEN ISLAND, N.Y., April 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 825,085 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.03 per share (or pre-funded warrant in lieu thereof) in a registered direct offering priced
- PRKorean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC InhibitorsSTATEN ISLAND, N.Y., March 30, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult‑to‑treat bacterial infections, today announced that the Korean Intellectual Property Office (KIPO) has granted a new patent which covers DNA Polymerase IIIC inhibitors including compositions‑of‑matter, methods of use, and pharmaceutical compositions, which further strengthen Acurx's intellectual property portfolio and represents the most recent addition to its expanding series of granted patents in the U.S. and abroad. To date, Acurx has secured four U.S. patents, alo
ACXP FAQ
7 questionsWhat does Acurx Pharmaceuticals Inc. do?
Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae...Where does ACXP stock trade?
Acurx Pharmaceuticals Inc. (ACXP) is listed on NASDAQ.What sector and industry is ACXP in?
Acurx Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Acurx Pharmaceuticals Inc. go public?
Acurx Pharmaceuticals Inc. (ACXP) completed its IPO in 2021.What are analysts saying about ACXP?
Acurx Pharmaceuticals Inc. has had 1 recent analyst action on file. The most recent action was from Maxim Group: Buy with a $1200.00 price target on 2021-11-29. Recent price targets cluster around $1200.00.What companies are similar to ACXP?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ACXP side-by-side with any of them on Quantisnow.How can I track ACXP on Quantisnow?
Quantisnow aggregates Acurx Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ACXP to receive live email and push alerts on every new disclosure.